---
title: CDMO Daily News — September 11, 2026
slug: daily-news-2026-09-11-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: September 11 CDMO daily: Cellipont and Xiogenix Validate Automated Fill-Finish for Cell Therapy Scale-Up; CordenPharma Expands Italy Injectable Capacity to…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-09-11-cdmo
published_at: 2026-09-11T00:02:42.376Z
last_updated: 2026-09-11T00:04:10.603Z
---

### Cellipont and [Xiogenix](/companies/cellipont-bioservices) Validate Automated Fill-Finish for Cell Therapy Scale-Up
- Collaborative white paper demonstrates [Xiogenix](/companies/cellipont-bioservices) ARES X20+ platform maintains formulation accuracy (98.2%–103.6%) across 17-fold process scale increase in cell therapy manufacturing.
- Automated platform preserved cell viability post-formulation and addressed downstream variability; enhancements implemented include priming, pressure monitoring, and gravimetric control.

**Operational Impact**

Cellipont's published validation of automated fill-finish scalability may reduce perceived risk for CDMO buyers evaluating cell therapy manufacturing capacity and process consistency as programs transition to larger clinical trials.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/cellipont-bioservices-and-xiogenix-assess-automated-cell-therapy-fill-finish)*

---

### [CordenPharma](/companies/cordenpharma) Expands Italy Injectable Capacity to 500M Units/Year
- [CordenPharma](/companies/cordenpharma) acquired 11,000 m² building and 26,000 m² land adjacent to its Caponago (Milan) site in July 2026, expanding footprint by >50% as part of €80M multi-year injectable CAPEX program.
- Two new aseptic fill & finish isolator lines—Bausch & Ströbel combo line and Syntegon high-speed PFS/cartridge line (>500K units/day)—targeted for completion mid-2027 and 2028, combined with doubled analytical capacity.
- Expanded facility will accommodate minimum four aseptic fill & finish lines, four visual inspection lines, and four packaging lines, supporting PFS, vials, cartridges, lyophilized formats, and auto-injectors across peptides, LNPs, small molecules, biologics, and oligonucleotides.

**Operational Impact**

[CordenPharma](/companies/cordenpharma)'s Caponago expansion adds 500M units/year of aseptic fill & finish capacity for peptides, LNPs, and biologics, with integrated LNP manufacturing on-site and completion phased through 2028, materially increasing European injectable CDMO availability for commercial-stage programs.

*Source: [Contract Pharma Breaking News RSS](https://www.contractpharma.com/breaking-news/cordenpharma-expands-injectable-manufacturing-in-italy)*

---

### EpilepsyGTx Selects [Viralgen](/companies/viralgen) for EPY201 AAV Gene Therapy Manufacturing
- EpilepsyGTx partners with [Viralgen](/companies/viralgen) to manufacture EPY201, an investigational AAV gene therapy for focal refractory epilepsy, ahead of first-in-human trials.
- Viralgen will deploy its Aava platform, which has produced 1,500 AAV batches and supports scalable manufacturing across AAV serotypes from early development through commercial scale.

**Operational Impact**

[Viralgen](/companies/viralgen)'s selection for EPY201 manufacturing demonstrates continued demand for its Aava platform in advancing AAV programs from IND-enabling studies into clinical development, reinforcing its position in early-stage gene therapy CDMO capacity.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/epilepsygtx-partners-with-viralgen-to-manufacture-epy201-gene-therapy)*

## References

1. [PharmaSource RSS — Cellipont and Xiogenix Validate Automated Fill-Finish for Cell Therapy Scale-Up](https://pharmasource.global/content/news/cdmo-news/cellipont-bioservices-and-xiogenix-assess-automated-cell-therapy-fill-finish)
2. [Contract Pharma Breaking News RSS — CordenPharma Expands Italy Injectable Capacity to 500M Units/Year](https://www.contractpharma.com/breaking-news/cordenpharma-expands-injectable-manufacturing-in-italy)
3. [PharmaSource RSS — EpilepsyGTx Selects Viralgen for EPY201 AAV Gene Therapy Manufacturing](https://pharmasource.global/content/news/cdmo-news/epilepsygtx-partners-with-viralgen-to-manufacture-epy201-gene-therapy)

Source: https://www.cdmo.directory/posts/daily-news-2026-09-11-cdmo